TOP TEN perturbations for 1553394_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553394_a_at
Selected probe(set): 214451_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553394_a_at (214451_at) across 6672 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):8.028277
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)

Relative Expression (log2-ratio):-7.3308225
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion.

stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):7.030656
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 9d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

skin squamous cell carcinoma study 6 / basal cell carcinoma study 2

Relative Expression (log2-ratio):-6.745082
Number of Samples:4 / 2
Experimental skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)

Relative Expression (log2-ratio):6.2005415
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion.
Control expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia.

expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)

Relative Expression (log2-ratio):-5.8590717
Number of Samples:3 / 2
Experimental expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS).
Control expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion.

basal cell carcinoma study 6 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):5.8164406
Number of Samples:15 / 14
Experimental basal cell carcinoma study 6 (primary)
Primary tumor tissue from the skin of patients with primary basal cell carcinoma (BCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):5.5815077
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (iDRG; 12d)
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

breast cancer study 50 (subtype II) / breast cancer study 50 (subtype I)

Relative Expression (log2-ratio):5.0720596
Number of Samples:34 / 37
Experimental breast cancer study 50 (subtype II)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype II. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype II:predominantly negative for ER, variable for PR expression, predominantly positive for HER2, larger tumors dominate (T-stage), propensity to develop distant metastases (47%), increased expressions of cell cycle/proliferation genes, high risk of distant recurrence
Control breast cancer study 50 (subtype I)
Primary tumor tissue samples obtained from the breast of patients with breast cancer with KFSYSCC subtype I. Samples were collected at the Koo Foundation Sun-Yat-Sen Cancer Center (KFSYSCC) between 1991 and 2004. Exclusion criteria: patients with follow-up periods shorter than three years, with the exception of patients who died of the disease within three years of the initial treatment. KFSYSCC subtype I:predominantly negative for ER, variable for PR expression, predominantly negative for HER2, in concordance with chemosensitive basal-like intrinsic type, CMF yielded survival outcome similar to those of CAF, increased expressions of cell cycle/proliferation genes, high risk of distant recurrence

expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (cribriform carcinoma; primary)

Relative Expression (log2-ratio):-5.015924
Number of Samples:2 / 2
Experimental expO breast cancer study 1 (medullary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS).
Control expO breast cancer study 1 (cribriform carcinoma; primary)
Primary tumor tissue samples obtained from the breast of patients with cribriform carcinoma.